Spectral AI Announces Appointment of Stanley Micek as Chief Operating Officer

Rhea-AI Summary

Spectral AI (NASDAQ: MDAI) has appointed Stanley Micek as permanent Chief Operating Officer, following his successful tenure as Interim COO since May 2024. Micek brings over 25 years of healthcare leadership experience, including previous roles as Senior Vice President for Business Development & Strategy at MiMedx and leadership positions at The Ohio State University Comprehensive Cancer Center. In his interim role, he has led the company's Research and Development group and overseen various teams working on FDA submission for their AI-powered wound diagnostic tool. Board Chairman Dr. J. Michael DiMaio praised Micek's exceptional leadership, operational insight, and ability to drive performance and cross-functional collaboration.

Positive

• Appointment of experienced healthcare executive with over 25 years of leadership experience
• Smooth transition from interim to permanent role indicates operational stability
• Strong progress on FDA submission under Micek's leadership
• Demonstrated success in leading R&D and cross-functional teams

Negative

• FDA approval still pending with uncertain timeline
• Potential learning curve in transition from interim to permanent role

DALLAS, May 30, 2025 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced that Stanley Micek has been named the Company’s Chief Operating Officer (“COO”). Micek’s promotion reflects his role change from Interim COO of the Company since May, 2024

“Stan has demonstrated exceptional leadership, operational insight, and a deep understanding of our business during his time as interim COO,” said Dr. J. Michael DiMaio, M.D., Chairman of the Company’s Board of Directors. “His efforts leading our Research and Development group and his ability to drive performance, foster cross-functional collaboration, and execute on strategic priorities made it clear that he was the right person to lead our operations moving forward.”

Since assuming the interim role, Micek has overseen the data science, software, hardware, imaging and systems teams working directly on our FDA submission.

Prior to becoming interim COO, Micek was the Senior Vice President for Business Development & Strategy at MiMedx and held numerous leadership roles at The Ohio State University at the Ohio State Comprehensive Cancer, bringing over 25 years of leadership experience in healthcare and acute wound expertise.

“I’m honored to continue this journey with Spectral AI and excited to lead our operations team as we build on our momentum from our recent Pivotal Burn Study,” said Micek. “Together, we’ll strive for excellence in providing a ground-breaking wound diagnostic tool and I am excited to work to drive our submission to the FDA in the near future.”

About Spectral AI

Spectral AI, Inc. is a Dallas-based predictive AI company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, with initial applications involving patients with burns. The Company is working to revolutionize the management of wound care by “Seeing the Unknown^®” with its DeepView^® System. The DeepView^® System is being developed as a predictive device to offer clinicians an objective and immediate assessment of a burn wound’s healing potential prior to treatment or other medical intervention. With algorithm-driven results and a goal of exceeding the current standard of care in the future, the DeepView^® System is expected to provide fast and accurate treatment insight towards value care by improving patient outcomes and reducing healthcare costs. For more information about the DeepView^® System, visit www.spectral-ai.com.

Forward-Looking Statements

Certain statements made in this release are “forward looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995, including statements regarding the Company’s strategy, plans, objectives, initiatives and financial outlook. When used in this press release, the words “estimates,” “projected,” “expects,” “anticipates,” “forecasts,” “plans,” “intends,” “believes,” “seeks,” “may,” “will,” “should,” “future,” “propose” and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside Company’s control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. As such, readers are cautioned not to place undue reliance on any forward-looking statements. 

Investors should carefully consider the foregoing factors, and the other risks and uncertainties described in the “Risk Factors” sections of the Company’s filings with the SEC, including the Registration Statement and the other documents filed by the Company. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. 

For Media and Investor Relations, please contact:  

David Kugelman  
Atlanta Capital Partners LLC  
(866) 692-6847 Toll Free - U.S. & Canada  
(404) 281-8556 Mobile and WhatsApp  
Email: dk@atlcp.com 

FAQ

Who is Stanley Micek and what is his new role at Spectral AI (MDAI)?

Stanley Micek has been appointed as the permanent Chief Operating Officer of Spectral AI, following his role as Interim COO since May 2024. He brings over 25 years of healthcare leadership experience.

What is Spectral AI's (MDAI) main business focus?

Spectral AI is an artificial intelligence company focused on medical diagnostics for faster and more accurate treatment decisions in wound care.

What was Stanley Micek's previous experience before joining Spectral AI (MDAI)?

Micek previously served as Senior Vice President for Business Development & Strategy at MiMedx and held leadership roles at The Ohio State University Comprehensive Cancer Center.

What are Stanley Micek's current responsibilities at Spectral AI (MDAI)?

Micek oversees the data science, software, hardware, imaging and systems teams working on FDA submission, and leads the company's operations and Research and Development group.

What is the status of Spectral AI's (MDAI) FDA submission?

The company is currently working on their FDA submission following their recent Pivotal Burn Study, with plans to submit in the near future.